Abstract: Antibody⁃drug conjugate (ADC) facilitate precise targeting of non⁃small cell lung cancer (NSCLC) by delivering potent cytotoxic agents directly to tumor cells, but monotherapy with ADC limited by tumor heterogeneity and acquired resistance. In recent years, combination therapy strategies that integrate ADC with immune checkpoint inhibitors and targeted agents have demonstrated superior efficacy in driver gene⁃negative NSCLC. This approach not only offers a chemotherapy⁃sparing treatment model, but also significantly transforms the therapeutic landscape for advanced NSCLC. This review aims to systematically summarize the biological mechanisms and the latest clinical advances of ADC⁃based combination therapy, while also exploring key challenges and future directions. It seeks to provide a theoretical foundation and clinical practical insights for precision treatment in advanced NSCLC.

Key words: Non?small cell lung cancer, Antibody?drug conjugate, Combination therapy, Precision medicine